Skip to main content
Quest Diagnostics

Health Trends® Report

The growing crisis of Novel Psychoactive Substances

Our most recent Health Trends® report, Drug Misuse in America 2023: the Growing Crisis of Novel Psychoactive Substances (NPS), examines more than 3.6 million deidentified clinical drug tests in 2022. The report reveals new insights into the drug crisis and its shifts from misuse of prescription opioids to NPS such as xylazine, which is routinely found in combination with other substances, including fentanyl.

Fill out the form below to download our latest findings on drug use and misuse across the country.

Please remember that email, including this web form, is not a secure method of communication. Do not submit personal information, including usernames and passwords, social security numbers, or personal health information through this form.

* indicates required

Drug toxicology consultation for healthcare providers

For assistance with prescription drug monitoring results, please contact Quest Diagnostics toxicology consultant specialists. They are available Monday – Friday, 8:00 AM to 10:00 PM Eastern Time.

 

1.877.40.RXTOX (1.877.407.9869)

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.